摘要
目的:探析采用安罗替尼联合化疗治疗驱动基因阴性晚期非小细胞肺癌的临床效果。方法:从2019年3月—2022年3月景德镇市第三人民医院诊治的驱动基因阴性晚期非小细胞肺癌患者中选择98例作为研究对象,按照随机数字表法将其分为对照组和观察组,两组均为49例,其中对照组采用单纯化疗(含铂双药疗法)治疗,观察组采用安罗替尼及化疗(含铂双药疗法)联合治疗。对两组治疗后的临床效果(总有效率、疾病控制率)、药物不良反应进行比较,同时对两组治疗前及治疗2个疗程后的血清学肿瘤标志物(血清癌胚抗原、细胞角蛋白19片段)水平进行对比。结果:观察组治疗总有效率、疾病控制率均高于对照组(P<0.05);观察组治疗后药物不良反应发生率低于对照组,差异无统计学意义(P>0.05);观察组治疗后血清癌胚抗原、细胞角蛋白19片段水平均低于对照组(P<0.05)。结论:在驱动基因阴性晚期非小细胞肺癌患者中采用安罗替尼及化疗(含铂双药疗法)联合治疗,近期临床疗效良好,肿瘤标志物表达含量下降,安全性较高。
Objective:To discussion and analysis the clinical effect of Anlotinib combined with chemotherapy in the treatment of driver gene negative advanced non-small cell lung cancer.Method:A total of 98 patients with advanced non-small cell lung cancer diagnosed and treated in the Third People's Hospital of Jingdezhen from March 2019 to March 2022 were selected as research objects.According to the random number table method,they were divided into the control group and the observation group,with 49 cases in both groups.The control group was treated with chemotherapy alone(double-drug therapy containing Carboplatin platinum).The observation group was treated with the combination of Anlotinib and chemotherapy(double-drug therapy containing Carboplatin).The clinical effects(total effective rate,disease control rate)and adverse drug reactions after treatment were compared between the two groups.At the same time,the levels of serological tumor markers(serum carcinoembryonic antigen,cytokeratin 19 fragment)were compared between the two groups before treatment and after 2 courses of treatment.Result:The total effective rate and disease control rate of the observation group were higher than those of the control group(P<0.05);after treatment,the incidence of adverse drug reactions in the observation group was lower than that in the control group,with no significant difference(P>0.05);the levels of serum carcinoembryonic antigen and cytokeratin 19 fragment in the observation group were lower than those in the control group(P<0.05).Conclusion:In the patients with driver gene negative advanced non-small cell lung cancer,the combination therapy of Anlotinib and chemotherapy(double-drug therapy containing Carboplatin)can show good clinical efficacy in the near term,decreas expression of tumor markers and have high safety.
作者
夏甜甜
XIA Tiantian(The Third People's Hospital of Jingdezhen,Jiangxi Province,Jingdezhen 333000,China)
出处
《中国医学创新》
CAS
2023年第25期47-50,共4页
Medical Innovation of China
作者简介
通信作者:夏甜甜。
